Urea cycle disorder treatment market to hit $215.4m by 2028

It is driven by the increasing prevalence of UCDs.

The global urea cycle disorder (UCD) treatment market is projected to grow by $215.4m from 2024 to 2028, at a CAGR of 3.2%, according to Technavio.

Rising healthcare investments in developing countries are key factors in this growth.

According to the report, India and China are seeing an increase in hospital numbers and healthcare spending, creating a significant opportunity for UCD treatment providers.

Additionally, the demand for advanced screening and UCD management is growing due to a rise in metabolic disorders.

Despite the market’s growth, challenges remain due to limited access to specialised care, particularly in remote regions. The complex nature of UCD treatment, which involves dietary changes, medications, and ammonia monitoring, contributes to delayed diagnoses and inadequate treatment.

It added that the pandemic disrupted pharmaceutical research and supply chains, but the demand for UCD treatments, especially oral and injectable options, remains strong.

Meanwhile, the market is expected to continue expanding as healthcare systems adapt and innovate in UCD care.